

PTO/SB/08A and B (08-03) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>	<b>APPLICATION NO.:</b> 10/674,268	<b>FILING DATE:</b> September 29, 2003
	<b>FIRST NAMED INVENTOR:</b> Michael Fantuzzi	<b>ART UNIT:</b> 1652
	<b>EXAMINER NAME:</b> Kosson, Rosanne	<b>ATTY. DOCKET NO.:</b> 33503/US

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS*	Cite No.	PATENT NUMBER	ISSUE DATE	Name of Patentee of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
	A1.	4,029,760	06/1977	De Roeck born Holtzhauer	
	A2.	4,559,222	12/1985	Enscore et al.	
	A3.	5,290,605	03/1994	Shapira	
	A4.	5,298,246	03/1994	Yano et al.	
	A5.	5,431,916	07/1995	White	
	A6.	5,716,928	02/1998	Benet et al.	
	A7.	5,858,401	01/1999	Bhalani et al.	
	A8.	5,968,987	10/1999	Charman et al.	
	A9.	5,980,939	11/1999	Kim et al.	
	A10.	6,096,338	08/2000	Lacy et al.	
	A11.	6,121,234	09/2000	Benet et al.	
	A12.	6,174,547	01/2001	Dong et al.	
	A13.	6,197,349	03/2001	Westesen et al.	
	A14.	6,200,550	03/2001	Masterson et al.	
	A15.	6,207,137	03/2001	Shuch et al.	
	A16.	6,284,268	09/2001	Mishra et al.	
	A17.	6,368,618	04/2002	Jun et al.	
	A18.	6,503,483	01/2003	Shuch et al.	
	A19.	6,552,004	04/2003	Elazhary et al.	
	A20.	6,569,463	05/2003	Patel et al.	
	A21.	6,630,170	10/2003	Balkus et al.	
	A22.	6,730,319	05/2004	Maeder et al.	
	A23.	6,790,465	09/2004	Weissman	
	A24.	7,588,786	09/2009	Khan et al.	
	A25.	7,713,523	05/2010	Fantuzzi et al.	

U.S. PUBLICATION DOCUMENTS					
EXAMINER INITIALS*	Cite No. <sup>1</sup>	PUBLICATION NUMBER	PUBLICATION DATE	Name of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		
	B1.	2003/0108600	06/2003	Okibayashi et al.	

PTO/SB/08A and B (08-03) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>APPLICATION NO.:</b> 10/674,268	<b>FILING DATE:</b> September 29, 2003
	<b>FIRST NAMED INVENTOR:</b> Michael Fantuzzi	<b>ART UNIT:</b> 1652
	<b>EXAMINER NAME:</b> Kosson, Rosanne	<b>ATTY. DOCKET NO.:</b> 33503/US

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>1</sup>	DOCUMENT NUMBER	PUBLICATION DATE	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	MM-DD-YYYY			
	C1.	JP S57142911	09/1982	Motoyama et al.		√
	C2.	JP 5770815	05/1982	Furointo Sangyo KK	Abstract only.	√
	C3.	JP S57042616	03/1982	Freund Sangyo KK		√
	C4.	WO 98/056368	12/1998	Board of Regents, The University of Texas System		

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS <sup>1</sup>	Cite No. <sup>1</sup>	Include name of Author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D1.	Office Action dated December 7, 2010, JP 2006-528309, 5 pages (including English translation)	
	D2.	Office Action dated July 4, 2011, Israel Patent Application No. 174624, 2 pages	
	D3.	Anderson Provisional Patent Application No. 60/253,874, David M. Anderson, Applicant, filed November 29, 2000, 21 pages	
	D4.	Al-Hasso, Shahla, "Coenzyme Q10: A Review," <i>Hospital Pharmacy</i> , Vol. 36, No. 1, pp. 51-55, 2000 Facts and Comparisons	
	D5.	AUTHOR UNKNOWN, Oilseeds International Ltd., Rice bran oil- a health benefit, <a href="http://www.oilseedssf.com/products/prod.rice.html">http://www.oilseedssf.com/products/prod.rice.html</a> , 2002, printed on March 6, 2006; 2 pages	
	D6.	AUTHOR UNKNOWN, Paul Karrer Biography, Nobel Prizes, Nobel Prize in Chemistry, <a href="http://nobelprize.org">nobelprize.org</a> , printed on January 5, 2007, 2 pages	
	D7.	COMAX Q10 Trademark Registration Abstract and copy of Specimen, Registration No. 1764014, registered April 13, 1993, 26 pages	
	D8.	CONSTANTINESCU, et al., "A Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinon)," <i>The Journal of Clinical Pharmacology</i> , 2007; 47: 1580-1586.	
	D9.	KANG et al., "Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport," <i>International Journal of Pharmaceutics</i> , 206 (2000) 35-42.	
	D10.	KAPLUN-FRISCHOFF, et al., "Testosterone Skin Permeation Enhancement by Menthol through Formation of Eutectic with Drug and Interaction with Skin Lipids," <i>Journal of Pharmaceutical Sciences</i> , Vol. 86, No. 12, December 1997, pp. 1394-1399	
	D11.	KOMMURU, et al., "A simplified chromatographic method for quantitative determination of coenzyme Q10 in dog plasma," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 16 (1998) 1037-1040.	

PTO/SB/08A and B (08-03) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for Form 1449A/PTO	APPLICATION NO.: 10/674,268	FILING DATE: September 29, 2003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FIRST NAMED INVENTOR: Michael Fantuzzi	ART UNIT: 1652
	EXAMINER NAME: Kosson, Rosanne	ATTY. DOCKET NO.: 33503/US

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
	D12.	KOMMURU, et al., "Stability and Bioequivalence Studies of Two Marketed Formulations of Coenzyme Q10 in Beagle Dogs," <i>Chem. Pharm. Bull.</i> 47(7) 1024-1028 (1999)	
	D13.	KOMMURU, et al., "Racemate and Enantiomers of Ketoprofen: Phase Diagram, Thermodynamic Studies, Skin Permeability, and Use of Chiral Permeation Enhancers," <i>Journal of Pharmaceutical Sciences</i> Vol. 87, No. 7, July 1998, pp. 833-840.	
	D14.	Nazzal et al., "Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation," <i>International Journal of Pharmaceutics</i> 235 (2002) 247-265.	
	D15.	Nazzal et al., "Response Surface Methodology for the Optimization of Ubiquinone Self-Nanoemulsified Drug Delivery System," <i>AAPS PharmSciTech</i> 2002; 3 (1) article 3, pp. 1-9, Published: February 8, 2002, found at URL: <a href="http://www.aapspharmscitech.org">http://www.aapspharmscitech.org</a>	
	D16.	POUTON, Colin W., "Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems," <i>European Journal of Pharmaceutical Sciences</i> 11 Suppl. 2 (2000) S93-S98.	
	D17.	Shojaei et al., "Transbuccal permeation of a nucleoside analog, dideoxycytidine: effects of menthol as a permeation enhancer," <i>International Journal of Pharmaceutics</i> 192 (1999) 139-146.	
	D18.	SHRESTHA et al., "Aqueous Phase Behavior of Diglycerol Fatty Acid Esters," <i>Journal of Dispersion Science and Technology</i> , 28: pp. 883-891, 2007.	
	D19.	Siekman et al., "Preparation and Physicochemical Characterization of Aqueous Dispersions of Coenzyme Q10 Nanoparticles," <i>Pharmaceutical Research</i> , Vol. 12, No. 2, 1995.	
	D20.	WEBER, et al., "Intestinal Absorption of Coenzyme Q10 Administered in a Meal or as Capsules to Healthy Subjects," <i>Nutrition Research</i> , Vol. 17, No. 6, pp. 941-945, 1997.	

PROSECUTION DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Name of document, date, application number, number of pages
		USSN 10/953,328 (33503/US/3)
	E1.	Decision on Appeal dated May 11, 2011, USSN 10/953,328, 9 pages
	E2.	Office Action dated May 18, 2011, USSN 10/953,328, 9 pages
	E3.	Amendment and Response to Office Action and Terminal Disclaimer dated August 18, 2011, USSN 10/953,328, 9 pages
	E4.	Terminal Disclaimer dated September 2, 2011, USSN 10/953,328, 2 pages
		USSN 11/223,718 (33503/US/5)
	E5.	Final Office Action dated July 14, 2011, USSN 11/223,718, 5 pages

<b>PTO/SB/08A and B (08-03)</b> <b>U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE</b> <b>Substitute for Form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>	<b>APPLICATION NO.:</b> 10/674,268	<b>FILING DATE:</b> September 29, 2003
	<b>FIRST NAMED INVENTOR:</b> Michael Fantuzzi	<b>ART UNIT:</b> 1652
	<b>EXAMINER NAME:</b> Kosson, Rosanne	<b>ATTY. DOCKET NO.:</b> 33503/US

<b>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</b>			
Examiner Signature	/Rosanne Kosson/	Date Considered	09/30/2011

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

4825-4857-1146/1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RK/